Due to their small size and high specificity, recombinant VHH constructs are increasingly
being used in therapeutic applications, such as CAR-T therapy. To track VHH in patients, animal models,
and cell cultures, specific anti-VHH antibodies are required. Techniques such as flow cytometry can then
be used to study the modified T cells, and cells can be sorted and used for downstream applications.
GenScript MonoRab™ Rabbit Anti-VHH antibodies show ultra-high specificity for VHH-based
CAR T cells. They are able to accurately detect the amount of VHH-based CAR T cells in samples, as shown
in Figure 3. The MonoRab™ Rabbit Anti-VHH antibodies can also be used in CAR-T cell determination and
sorting (Figure 4) by magnetic-activated cell sorting (MACS).
Figure 3. The above data shows FACS binding of a series of dilutions of MonoRab™ Rabbit Anti-Camelid VHH
Cocktail [PE] (Cat. No. A02018) with Jurkat cells and samples containing 20% of VHH-based Jurkat-CAR
cells. With the development of CAR-T therapy, VHH is often used in CAR generation. A02018 shows
excellent binding activity on VHH-based Jurkat-CAR cells. It is used for CAR-T cell verification and
Figure 4. VHH-based CAR-T cells were sorted by MACS with MonoRab™ Rabbit Anti-Camelid VHH Cocktail
[Biotin] (Cat. No. A02015) and anti-Biotin magnetic nanobeads (Miltenyi) where naïve T cells served as
negative control. Then, the CAR-T cells were stained with MonoRab™ Rabbit Anti-Camelid VHH Cocktail
[iFluor 555] (Cat. No. A02020) and analyzed by FACS.
As shown in the figure, the ratio of positive CAR-T
cells grows form about 10% to 90% after MACS cell separation. A02015 is ideal to be used for CAR-T cell